The FDA has approved Bracco’s gadopiclenol-based contrast agent, Vueway, for IV MRI imaging in neonates and infants.
Vueway is a macrocyclic gadolinium-based contrast agent that delivers effective image enhancement at half the gadolinium dose used in other approved macrocyclic agents, according to a Feb. 23 news release. The approval follows pediatric data from a non-randomized clinical trial and marks an extension from the product’s original 2022 FDA approval for adults and children ages 2 and older.
The expanded label provides clinicians with a low-dose contrast option for the youngest patients, a population especially vulnerable to cumulative exposure. Pediatric radiology leaders said the approval supports safer diagnostic imaging without compromising quality.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
